Skip to content
Subscriber Only

AbbVie, Roche Drug Wins U.S. Approval to Treat Type of Leukemia

  • Venclexta targets chronic lymphocytic leukemia, a blood cancer
  • Therapy can be used by patients considered hard to treat

AbbVie Inc. and Roche Holding AG’s treatment for a type of leukemia won U.S approval almost three months ahead of schedule.

The Food and Drug Administration approved Venclexta, known chemically as venetoclax, for patients with chronic lymphocytic leukemia who have tried at least one other therapy, according to a statement from the agency on Monday. Chronic lymphocytic leukemia is one of the most common types of blood cancer in adults, according to the National Cancer Institute.